Abstract
BackgroundVerinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia.ObjectivesThis Phase 1, single-blind, multiple dose, drug-drug interaction (DDI) study...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
